Abstract: A method for aggregated storage of observational data on a blockchain includes: receiving, by a receiver of a processing server, a plurality of data entries, wherein the plurality of data entries includes (i) one or more data entries received from each of a plurality of different external devices, or (ii) multiple data entries received from one external device; canonicalize, by a processor of the processing server, the received plurality of data entries into a single data value; hashing, by the processor of the processing server, the single data value to generate a hashed data value; transmitting, by a transmitter of the processing server, the hashed data value to a blockchain node in a blockchain network; receiving, by the receiver of the processing server, a reference value from the blockchain node; and storing, in a memory of the processing server, the received reference value with the plurality of data entries.

Abstract: A method for triggering payment transactions through predetermined events identified using a blockchain includes: receiving, at a first system, trigger data including a first account identifier, second account identifier, and trigger event values; receiving, at the first system, blockchain data values, each including a hash value; identifying, by the first system, a match between a specific blockchain data value and a specific trigger event value based on the hash value; transmitting, by the first system, a notification message to a second system including the first account identifier and second account identifier; identifying, by the second system, a first payment identifier using the first account identifier and a second payment identifier using the second account identifier; and initiating, by the second system, a payment transaction for payment from a transaction account associated with the first payment identifier to a transaction account associated with the second payment identifier.

Abstract: Provided herein are, inter alia, microbial compositions and methods of using the same. The microbial compositions provided include, inter alia, therapeutically effective amounts of Lactobacillus johnsonii, Faecalibacterium prausnitzii, Akkermansia muciniphila, Myxococcus xanthus and Pediococcus pentosaceus and are particularly useful for methods of treating and preventing inflammatory diseases.

Abstract: Provided herein are, inter alia, microbial compositions and methods of using the same. The microbial compositions provided include, inter alia, therapeutically effective amounts of Lactobacillus johnsonii, Faecalibacterium prausnitzii, Akkermansia muciniphila, Myxococcus xanthus and Pediococcus pentosaceus and are particularly useful for methods of treating and preventing inflammatory diseases.

Abstract: Provided herein are, inter alia, methods, compositions, and systems, for detecting and treating dysbiosis such as nasal and sinus dysbiosis. In aspects, included herein are methods, compositions, and systems for detecting asthma, chronic rhinosinusitis, and infections (such as rhinovirus infections), and methods of treating such disorders. Also provided are methods, compositions, and systems for detecting whether a subject has an increased risk of asthma, an infection, asthma exacerbation, chronic rhinosinusitis, or nasal polyposis, as well as methods of treating at-risk subjects. Methods, compositions, and systems for monitoring subjects diagnosted as having a disease or risk as disclosed herein are also included.

Abstract: Provided herein are, inter alia, methods, compositions, and systems, for detecting and treating lung dysbiosis. In aspects, included herein are methods, compositions, and systems for detecting infections (such as Aspergillus sp. infections and Mycobacterium sp. infections), or the risk thereof, as well as for treating such infections. Also provided are methods, compositions, and systems for detecting whether a subject who has pneumonia and is infected with HI has an increased risk of dying compared to a general population of subjects who have pneumonia and are infected with HIV. Methods, compositions, and systems for monitoring subjects diagnosted as having a disease or risk as disclosed herein are also included.

Abstract: Provided herein are, inter alia, microbial compositions and methods of using the same. The microbial compositions provided include, inter alia, therapeutically effective amounts of Lactobacillus johnsonii, Faecalibacterium prausnitzii, Akkermansia muciniphila, Myxococcus xanthus and Pediococcus pentosaceus and are particularly useful for methods of treating and preventing inflammatory diseases.

Abstract: Provided herein are compositions for improving sinus microbiota and treating sinusitis. Further provided are methods of detecting imbalance in the sinus microbiota that can be indicative of sinusitis, and methods of determining whether an individual has or is at risk of developing sinusitis, e.g., chronic sinusitis.

Abstract: Provided herein are, inter alia, microbial compositions and methods of using the same. The microbial compositions provided include, inter alia, therapeutically effective amounts of Lactobacillus johnsonii, Faecalibacterium prausnitzii, Akkermansia muciniphila, Myxococcus xanthus and Pediococcus pentosaceus and are particularly useful for methods of treating and preventing inflammatory diseases.

Abstract: Provided herein are, inter alia, microbial compositions and methods of using the same. The microbial compositions provided include, inter alia, therapeutically effective amounts of Lactobacillus johnsonii, Faecalibacterium prausnitzii, Akkermansia muciniphila, Myxococcus xanthus and Pediococcus pentosaceus and are particularly useful for methods of treating and preventing inflammatory diseases.

Abstract: Provided herein are compositions for improving sinus microbiota and treating sinusits. Further provided are methods of detecting imbalance in the sinus microbiota that can be indicative of sinusitis, and methods of determining whether an individual has or is at risk of developing sinusitis, e.g., chronic sinusitis.

Abstract: Provided herein are compositions for improving sinus microbiota and treating sinusits. Further provided are methods of detecting imbalance in the sinus microbiota that can be indicative of sinusitis, and methods of determining whether an individual has or is at risk of developing sinusitis, e.g., chronic sinusitis.

Abstract: Methods and systems for designing and using organism specific and/or operational taxon unit (OTU)-specific probes. The methods and systems allow for detecting, identifying and quantitating a plurality of biomolecules or microorganisms in a sample based on the hybridization or binding of target molecules in the sample with the probes, including the detection of rare OTU's in a sample. In some cases, methods are provided for selecting an oligonucleotide probe specific for a node on a clustering tree.

Abstract: A breathing arrangement includes a patient interface, at least one inlet conduit, and a headgear assembly. The patient interface includes a mouth covering assembly including a cushion structured to sealingly engage around exterior of a patient's mouth in use, a nozzle assembly including a pair of nozzles structured to sealingly engage within nasal passages of a patient's nose in use, and a flexible element connecting the mouth covering assembly and the nozzle assembly. The at least one inlet conduit is structured to deliver breathable gas into at least one of the mouth covering assembly and the nozzle assembly for breathing by the patient. The headgear assembly is removably connected to at least one of the mouth covering assembly and the nozzle assembly so as to maintain the mouth covering assembly and the nozzle assembly in a desired position on the patient's face.

Abstract: The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with Pseudomonas aeruginosa infections, where the method comprises administering an antibiotic and an anti-PcrV antibody.

Abstract: A breathing arrangement includes a patient interface, at least one inlet conduit, and a headgear assembly. The patient interface includes a mouth covering assembly including a cushion structured to sealingly engage around exterior of a patient's mouth in use, a nozzle assembly including a pair of nozzles structured to sealingly engage within nasal passages of a patient's nose in use, and an element connecting the mouth covering assembly and the nozzle assembly. The at least one inlet conduit is structured to deliver breathable gas into at least one of the mouth covering assembly and the nozzle assembly for breathing by the patient. The headgear assembly is removably connected to at least one of the mouth covering assembly and the nozzle assembly so as to maintain the mouth covering assembly and the nozzle assembly in a desired position on the patient's face.

Abstract: A nasal assembly for delivering breathable gas to a patient includes a frame having an integrally formed first connector portion. A nozzle assembly includes a gusset or base portion and a pair of nozzles. At least one inlet conduit is structured to deliver breathable gas into the frame and nozzle assembly for breathing by the patient. A pair of second connector portions are removably and rotatably connected to respective first connector portions of the frame and are in communication with respective inlet conduits, e.g., directly or via angle connectors. A headgear assembly is removably connected to the pair of second connector portions and/or the angle connectors so as to maintain the frame and the nozzle assembly in a desired adjusted position on the patient's face.

Abstract: A nasal assembly for delivering breathable gas to a patient includes a frame having an integrally formed first connector portion. A nozzle assembly includes a gusset or base portion and a pair of nozzles. At least one inlet conduit is structured to deliver breathable gas into the frame and nozzle assembly for breathing by the patient. A pair of second connector portions are removably and rotatably connected to respective first connector portions of the frame and are in communication with respective inlet conduits, e.g., directly or via angle connectors. A headgear assembly is removably connected to the pair of second connector portions and/or the angle connectors so as to maintain the frame and the nozzle assembly in a desired adjusted position on the patient's face.

Abstract: A nasal assembly for delivering breathable gas to a patient includes a frame having an integrally formed first connector portion. A nozzle assembly includes a gusset or base portion and a pair of nozzles. At least one inlet conduit is structured to deliver breathable gas into the frame and nozzle assembly for breathing by the patient. A pair of second connector portions are removably and rotatably connected to respective first connector portions of the frame and are in communication with respective inlet conduits, e.g., directly or via angle connectors. A headgear assembly is removably connected to the pair of second connector portions and/or the angle connectors so as to maintain the frame and the nozzle assembly in a desired adjusted position on the patient's face.

Abstract: A nasal assembly for delivering breathable gas to a patient includes a frame having an integrally formed first connector portion. A nozzle assembly includes a gusset or base portion and a pair of nozzles. At least one inlet conduit is structured to deliver breathable gas into the frame and nozzle assembly for breathing by the patient. A pair of second connector portions are removably and rotatably connected to respective first connector portions of the frame and are in communication with respective inlet conduits, e.g., directly or via angle connectors. A headgear assembly is removably connected to the pair of second connector portions and/or the angle connectors so as to maintain the frame and the nozzle assembly in a desired adjusted position on the patient's face.